X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-11-19 | EXAS | Orville Jacob A | EVP, GM, Screening | S - Sale | $75.00 | -5,000 | 24,727 | -17% | -$375,000 | ||||||
2025-11-19 | EXAS | Herriott James | SVP, GC, Sec | S - Sale | $70.00 | -1,000 | 13,141 | -7% | -$70,000 | ||||||
2025-11-04 | EXAS | Herriott James | SVP, GC, Sec | S - Sale | $70.08 | -1,500 | 14,141 | -10% | -$105,120 | ||||||
2025-11-04 | EXAS | Baranick Brian | EVP, GM, Precision Oncology | S - Sale | $70.08 | -2,858 | 23,038 | -11% | -$200,289 | ||||||
2025-10-24 | EXAS | Zanotti Katherine S | Dir | S - Sale | $65.00 | -12,000 | 60,759 | -16% | -$780,000 | ||||||
2025-10-09 | EXAS | Herriott James | SVP, GC, Sec | S - Sale | $60.00 | -1,500 | 15,641 | -9% | -$90,000 | ||||||
2025-10-09 | EXAS | Doyle James Edward | Dir | S - Sale | $60.00 | -2,000 | 57,962 | -3% | -$120,000 | ||||||
2025-08-13 | EXAS | Doyle James Edward | Dir | S - Sale | $42.02 | -1,485 | 59,962 | -2% | -$62,400 | ||||||
2025-06-13 | EXAS | Zanotti Katherine S | Dir | S - Sale | $53.20 | -3,207 | 72,759 | -4% | -$170,612 | ||||||
2024-11-13 | EXAS | Conroy Kevin T | Pres, CEO | P - Purchase | $51.35 | +19,500 | 1,414,311 | +1% | +$1,001,325 | ||||||
2024-10-08 | EXAS | Baranick Brian | EVP, GM, Precision Oncology | S - Sale | $70.00 | -929 | 13,212 | -7% | -$65,030 | ||||||
2024-09-18 | EXAS | Baranick Brian | EVP, GM, Precision Oncology | S - Sale | $70.00 | -929 | 14,141 | -6% | -$65,030 | ||||||
2024-05-01 | EXAS | Coward D Scott | Dir | S - Sale | $60.15 | -67 | 49,337 | 0% | -$4,030 | ||||||
2024-05-01 | EXAS | Cunningham Everett | Chief Commercial Officer | S - Sale | $60.15 | -136 | 47,613 | 0% | -$8,180 | ||||||
2024-05-01 | EXAS | Herriott James | SVP, GC, Sec | S - Sale | $60.15 | -30 | 11,049 | 0% | -$1,805 | ||||||
2024-05-01 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale | $60.15 | -136 | 13,380 | -1% | -$8,180 | ||||||
2024-05-01 | EXAS | Baranick Brian | EVP, GM., Precision Oncology | S - Sale | $60.15 | -110 | 13,733 | -1% | -$6,617 | ||||||
2024-05-01 | EXAS | Condella Sarah | EVP, HR | S - Sale | $60.15 | -102 | 78,337 | 0% | -$6,135 | ||||||
2024-05-01 | EXAS | Orville Jacob A | GM, Screening | S - Sale | $60.15 | -102 | 15,557 | -1% | -$6,135 | ||||||
2024-05-01 | EXAS | Conroy Kevin T | Pres, CEO | S - Sale | $60.15 | -1,155 | 1,394,770 | 0% | -$69,473 | ||||||
2024-04-01 | EXAS | Condella Sarah | EVP, HR | S - Sale | $70.00 | -2,000 | 77,513 | -3% | -$140,000 | ||||||
2024-04-02 | EXAS | Baranick Brian | EVP, GM., Precision Oncology | S - Sale | $79.43 | -924 | 13,625 | -6% | -$73,393 | ||||||
2024-03-28 | EXAS | Condella Sarah | EVP, HR | S - Sale | $70.00 | -2,000 | 79,513 | -2% | -$140,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |